Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Lorcaserin is a serotonin 5-hydroxytryptamine 2c receptor agonist effective in treating obesity. Studies in rodents have shown that lorcaserin acts in the brain to exert its weight-reducing effects, but this has not yet been studied in humans. We performed a randomized, placebo-controlled, double-bl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes
Hauptverfasser: Farr, Olivia M., Upadhyay, Jagriti, Gavrieli, Anna, Camp, Michelle, Spyrou, Nikolaos, Kaye, Harper, Mathew, Hannah, Vamvini, Maria, Koniaris, Anastasia, Kilim, Holly, Srnka, Alexandra, Migdal, Alexandra, Mantzoros, Christos S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Diabetes Association 2016
Schlagworte:
Obesity Studies
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5033259/
https://ncbi.nlm.nih.gov/pubmed/27385157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db16-0635
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge